Search results
Results From The WOW.Com Content Network
Neutropenia itself is a rare entity, but can be clinically common in oncology [35] and immunocompromised individuals as a result of chemotherapy (drug-induced neutropenia). Additionally, acute neutropenia can be commonly seen from people recovering from a viral infection or in a post-viral state.
Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia. [1] It is a leukocyte growth factor. [1] It is given by subcutaneous injection. [1] The most common side effects of efbemalenograstim alfa are nausea, anemia, and thrombocytopenia. [5]
Neutropenia, a subtype of leukopenia, refers to a decrease in the number of circulating neutrophil granulocytes, the most abundant white blood cells. The terms leukopenia and neutropenia may occasionally be used interchangeably, as the neutrophil count is the most important indicator of infection risk. Agranulocytosis is an acute form of ...
The treatment may mirror that of chemotherapy-induced myelosuppression or may be to change to an alternate drug or to temporarily suspend treatment. Because the bone marrow is the manufacturing center of blood cells, the suppression of bone marrow activity causes a deficiency of blood cells.
Thrombocytopenia, neutropenia, anaemia, hypotension and secondary malignancies. Ipilimumab: IV: CTLA4 antibody that causes immune system-mediated lysis of the tagged cell: Unresectable or metastatic malignant melanoma. Life-threatening immune mediated reactions and fever. Nivolumab: IV
A QSP model of neutrophil production and a PK/PD model of a cytotoxic chemotherapeutic drug (Zalypsis) have been developed to optimize the use of G-CSF in chemotherapy regimens with the aim to prevent mild-neutropenia. [15] G-CSF was first trialled as a therapy for neutropenia induced by chemotherapy in 1988.
The causes of monocytopenia include: acute infections, stress, treatment with glucocorticoids, aplastic anemia, hairy cell leukemia, acute myeloid leukemia, treatment with myelotoxic drugs, intestinal resection, and genetic syndromes, as for example MonoMAC syndrome. [3]
In people with cancer who have febrile neutropenia (excluding patients with acute leukaemia), oral treatment is an acceptable alternative to intravenous antibiotic treatment if they are hemodynamically stable, without organ failure, without pneumonia and with no infection of a central line or severe soft-tissue infection. [11]